Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Pancreatic Cancer: A Look Back at 2024

2024 saw progress in pancreatic cancer treatment with four new drug approvals, a phase 3 trial showing survival benefits, and the first phase 3 RAS inhibitor trial. The five-year survival rate rose to 13%, though pancreatic cancer remains challenging. Targeted therapies and biomarker testing are crucial, with new options like NALIRIFOX, KRAS inhibitors, and TTFields offering hope.

Related Clinical Trials:

Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

ipsen.com

2 months ago

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full ...

Ipsen reports YTD 2024 total sales growth of 9.2% at CER, driven by Dysport, Cabometyx, and Bylvay. Regulatory approvals for Iqirvo and Kayfanda, and increased 2024 guidance: total-sales growth >8.0% at CER, core operating margin >31.0%.

medcitynews.com

3 months ago

SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition

Ipsen employee Dishant Gupta charged with insider trading after allegedly profiting from stock transactions based on non-public knowledge of the company's $247 million buyout of Epizyme. Gupta, who agreed to plead guilty, faces a monetary penalty and is barred from serving as an executive or director of any publicly traded company. Ipsen's oncology portfolio expansion includes acquisitions like Epizyme's Tazverik and Merrimack Pharmaceuticals' Onivyde, along with deals for cancer drug development programs.